GSK says RSV vac­cine trig­gered im­mune re­sponse in adults as young as 50 years old

GSK read out Phase III re­sults on Wednes­day sug­gest­ing that its res­pi­ra­to­ry syn­cy­tial virus vac­cine — cur­rent­ly ap­proved for the 60-and-old­er pop­u­la­tion — may trig­ger an im­mune …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER